Developing a platform protocol for clinical trials evaluating interventions that target proposed mechanisms of [LC]: RECOVER-VITAL, 2026, Zimmerman+

[forestglip]

Developing a platform protocol for clinical trials evaluating interventions that target proposed mechanisms of Long COVID: RECOVER-VITAL

Spoiler: Authors

Kanecia O Zimmerman, Richard Whitley, Sean O’Brien, David R Walt, Bruce D Levy, Christine Maughan, Marta Cerda, Rachel Olson, Lucinda Bateman, Cyndya A Shibao, Barry Make, David Knopman, Susan Redline, Leonard A Jason, Mehul S Suthar, Phillip Low, Tracy L Nolen, Craig Reist, Lisa Berdan, Lindsey R Baden

Background
Long COVID, the chronic sequela of SARS-CoV-2 infection, has affected millions of people worldwide. However, its pathogenesis and treatment remain unknown. To address this critical gap, the National Institutes of Health (NIH) developed the Researching COVID to Enhance Recovery (RECOVER) Initiative that included the Viral Persistence and Reactivation, and Immune Dysregulation (RECOVER-VITAL) study as one of the first of five NIH-sponsored, integrated platform protocols to support the rigorous and rapid investigation of potential interventions for Long COVID.

Methods
Experts across academia, the NIH, and the community of patients and caregivers were brought together to design the RECOVER-VITAL protocol. We present the challenges and rationale underpinning critical components of this protocol and provide evidence for use of the platform for efficient execution of current and future Long COVID clinical trials.

Facets of the RECOVER-VITAL protocol, including inclusion criteria, intervention groups, study procedures, investigation of biomarkers, and endpoints, were carefully crafted to advance the current and future science and operations of Long COVID clinical trials, particularly in the absence of existing data.

The initial trial within the RECOVER-VITAL platform evaluated two durations of an antiviral drug, nirmatrelvir/ritonavir, to test the proposed etiology of viral persistence on the Long COVID symptom clusters of autonomic dysfunction, cognitive dysfunction, and exercise intolerance. The primary outcome measures were patient-reported, and secondary outcomes included performance-based measures for each of the symptom clusters of interest.

Conclusions
The RECOVER-VITAL platform protocol has substantial implications for the design and conduct of future Long COVID clinical trials.

Web | Clinical Trials | Paywall

 

[Hutan]

Unfortunately the Conclusions don't actually tell us what the substantial implications for the design and conduct of future Long COVID clinical trials are. I guess they want us to pay for access?

I'm not sure how that works. The trial was done by the NIH, presumably funded by US government funds? I can't imagine the 'community of patients and caregivers brought together' with the academics and NIH staff were well paid for their time. Similarly, I doubt the trial participants were well paid for being guinea pigs.

Long COVID is an international public health crisis and presumably this paper aims to improve future trials, in a field where low quality trials has been the norm. And yet, Sage Journals 'Clinical Trials' wants to charge people 32 pounds to have a look at it?

The primary outcome measures were patient-reported

They say it proudly like it's a good thing. Perhaps it is ok if the study was blinded and/or the secondary measures are objective. I can't say from the information in the abstract.

 

[V.R.T.]

The RECOVER-VITAL platform protocol has substantial implications for the design and conduct of future Long COVID clinical trials.

It's been five f-king years since RECOVER was announced! Five years. And they are giving themselves a congratulatory pat on the back for their trial design having achieved absolutely sweet f-a.

They have squandered a billion and a half dollars on treatments that were almost certain to fail and useless studies about how many long haulers report headaches or whatever. What happened to all the biobanking work? Why haven't they done a GWAS? Why are they not investigating the interesting findings that need replicating?

It's a collosal mess.